PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性研究
x

请在关注微信后,向客服人员索取文件

篇名: PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性研究
TITLE:
摘要: 目的:探讨外周动脉疾病(PAD)患者基因多态性与氯吡格雷抗血小板疗效的相关性。方法:收集近年来国内外相关文献,就PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性进行汇总、分析。结果与结论:目前已发现多种与氯吡格雷抗血小板疗效和主要心血管不良事件(MACE)相关的基因,包括细胞色素P450(CYP)2C19、腺苷三磷酸结合盒B亚家族成员1(ABCB1)、对氧磷酶1(PON1)和腺苷二磷酸P2Y12受体(P2Y12)等。其中,CYP2C19*2、*3等位基因可能会减弱氯吡格雷的抗血小板作用,两者的相关性已被多项研究证实,且结果具有广泛的一致性;ABCB1 C3435T、PON1 Q192R位点发生突变,可能会导致患者对氯吡格雷的反应性变低,增加MACE发生的风险,但缺乏大规模的前瞻性临床研究,且现有结果并不一致;尚未发现PAD患者P2Y12基因多态性与氯吡格雷疗效显著相关。
ABSTRACT: OBJECTIVE: To investigate the correlation of gene polymorphism in peripheral artery disease (PAD) patients with antiplatelet efficacy of clopidogrel. METHODS: Reviewing related domestic and foreign literatures in recent years, the correlation of gene polymorphism in PAD patients with antiplatelet efficacy of clopidogrel was summarized and analyzed. RESULTS&CONCLUSIONS: At present, a variety of genes associated with clopidogrel antiplatelet efficacy and major adverse cardiovascular events (MACE) have been identified, including cytochrome P450 (CYP) 2C19, adenosine three phosphate binding cassette B subfamily 1 (ABCB1), paraoxonase 1 (PON1) and adenosine diphosphate P2Y12 receptor (P2Y12), etc. CYP2C19*2, *3 allele may reduce the antiplatelet effect of clopidogrel. Their correlation has been confirmed by a number of studies, and study results are broadly consistent. Mutations in the ABCB1 C3435T and PON1 Q192R sites may lead to a lower response to clopidogrel and increase the risk of MACE; but there is a lack of large-scale prospective clinical studies, and the present results are inconsistent. P2Y12 gene polymorphism in PAD patients has not been found to be significantly associated with clopidogrel efficacy.
期刊: 2017年第28卷第26期
作者: 徐晓宇,林阳,石秀锦,续茜桥
AUTHORS: XU Xiaoyu,LIN Yang,SHI Xiujin,XU Xiqiao
关键字: 外周动脉疾病;氯吡格雷;基因多态性;CYP2C19基因;ABCB1基因;PON1基因;P2Y12基因;抗血小板作用
KEYWORDS: Peripheral artery disease; Clopidogrel; Gene polymorphism; CYP2C19 gene; ABCB1 gene; PON1 gene; P2Y12 gene; Antiplatelet efficacy
阅读数: 296 次
本月下载数: 5 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!